Eli Lilly (LLY)
798.89
+22.45 (2.89%)
NYSE · Last Trade: Jul 23rd, 10:59 PM EDT
Detailed Quote
Previous Close | 776.44 |
---|---|
Open | 780.00 |
Bid | 797.00 |
Ask | 797.50 |
Day's Range | 777.08 - 800.09 |
52 Week Range | 677.09 - 972.53 |
Volume | 2,683,559 |
Market Cap | 764.20B |
PE Ratio (TTM) | 65.00 |
EPS (TTM) | 12.3 |
Dividend & Yield | 6.000 (0.75%) |
1 Month Average Volume | 2,887,285 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside
Via MarketBeat · July 23, 2025
Via Benzinga · July 23, 2025
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.
Via Investor's Business Daily · July 23, 2025
Exchange-traded funds (ETFs) can be a lucrative source of wealth for patient investors.
Via The Motley Fool · July 23, 2025
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Via Benzinga · July 22, 2025
Via The Motley Fool · July 22, 2025
Buy-and-hold investing only works if you choose the right companies. Here are some potential examples.
Via The Motley Fool · July 22, 2025
At the center of the company’s plan is a new, multi-billion-dollar manufacturing facility in Virginia.
Via Stocktwits · July 21, 2025
Via The Motley Fool · July 21, 2025
Via The Motley Fool · July 21, 2025
Via The Motley Fool · July 20, 2025
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.
Via The Motley Fool · July 19, 2025
Via The Motley Fool · July 18, 2025
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · July 17, 2025
Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and nationwide delivery.
Via Benzinga · July 17, 2025
GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs altering consumer purchasing patterns.
Via Benzinga · July 17, 2025
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
Via StockStory · July 17, 2025
Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 4.1% in the morning session after the company successfully completed its strategic reorganization process and announced new program innovations.
Via StockStory · July 16, 2025
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Via Chartmill · July 16, 2025
Via Benzinga · July 16, 2025
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
Via Benzinga · July 16, 2025
Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.
Via MarketBeat · July 15, 2025
PolyPid’s Game-Changing 60-Day GLP-1 Platform Could Disrupt $100B Weight Loss Market
PolyPid Ltd. (NASDAQ: PYPD), a late-stage biopharma company with a market cap of just $35 million, has unveiled a potentially transformative approach to the red-hot GLP-1 market that could significantly disrupt how weight loss and diabetes medications are delivered to patients.
Via AB Newswire · July 15, 2025